I love it when things work out!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like more eyes are following SPYR. Spikes in volume like we saw yesterday will do that!
I don't recall when was the last time I checked, but I'm pretty sure the last time I did there were 30-some followers.
There are now 40 people following SPYR on Ihub.
As they continue to execute their business I'm guessing this number will increase.
I thought that big 493k offer might be scooped up before the close.
Guess we’ll see what tomorrow brings.
Volume for the day is certainly on the rise... presently setting at 771,713. Impressive.
The Buying was sparked by the purchase of an overhanging offer of 305281 shares in a single bite.
I’ve been following KAVL for a while. And since the reverse most trades have been for 100 or less and many under 1000 and many a trades or two a day for 1000 shares or maybe 1200.
This morning there were a couple trades for that broke the norm….
There was one was for 3587 shares and the other for 5000.
I’m not sure it means anything, but I think it could indicate that some bigger players entering the game.
We shall see.
The 10K bid at $.49 was pretty encouraging.
Too bad someone tapped it… Else we might be trading about 50 cents.
NEWS!! American Resources Corporation Selected as a Member in U.S. Department of Energy Contract to Assess Critical and Rare Earth Elements in Coal Resource Feedstocks
* Department of Energy has awarded multifaceted award to consortium to identify rare earth elements (REEs) from carbon-based deposits
* Program is to support the establishment of a domestic supply chain for rare earth and critical elements to support the growth of the electrification market
FISHERS, IN / ACCESSWIRE / August 25, 2021 / American Resources Corporation (NASDAQ:AREC) ("American Resources" or the "Company"), a next generation and socially responsible supplier of raw materials to the new infrastructure marketplace, announced today that the Company has been named to a U.S. Department of Energy (DOE) Federal Demonstration Partnership award for the sorting for critical mineral-rich coal resource feedstock in a support role. Under the agreement, American Resources will provide support to the DOE sponsored program lead by Microbeam Technologies Inc. (Microbeam) and Energy Technologies Inc. (ETI) to determine novel methods for predicting rare earth elements and critical minerals in different coal types utilizing prompt gamma neutron activation analysis (PGNAA) spectra technology.
Mark Jensen, CEO of American Resources Corporation commented, "We are pleased to join this effort in developing an innovative application in analyzing carbon-based feedstocks for their inherent critical and rare earth elements. We are extremely proud of the steps we have made in becoming an innovator, solutions provider, and leader in establishing an efficient, sustainable and environmentally-safe domestic supply chain for these increasingly important materials. As we continue the execution of our Capture - Process - Purify process chain, we are greatly encouraged by the collaborative opportunities we are seeing to participate in these exciting initiatives. We look forward to supporting both Microbeam and ETI with this innovative project and look forward to also broadening our partnerships to create real and safe solutions in how these materials are sourced and processed."
American Resources, to date, has acquired 16 patents and technologies specific to producing REEs and critical minerals from coal-based waste and byproducts as well as waste permanent magnets and lithium-ion batteries. The Company's "Capture - Process - Purify" process chain is focused on these specific feedstocks to create a highly sustainable and environmentally friendly supply source of these critical resources. The Company is committed to advancing its technology suite, which includes electrolysis processing and ligand-assisted chromatography purification, towards commercialization as efficiently and effectively as possible.
American Resources continues to focus on running efficient streamlined operations in being a new-aged supplier of raw materials to the infrastructure and electrification marketplace in the most sustainable of ways. By operating with low or no legacy costs and having one of the largest and most innovative growth pipelines in the industry, American Resources Corporation works to maximize value for its investors by positioning its large asset base to best fit a new-aged economy, while being able to scale its operations to meet the growth of the markets it serves.
About American Resources Corporation
American Resources Corporation is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated.
American Resources has established a nimble, low-cost business model centered on growth, which provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets while also continuing to acquire operations and significantly reduce their legacy industry risks. Its streamlined and efficient operations are able to maximize margins while reducing costs. For more information visit americanresourcescorp.com or connect with the Company on Facebook, Twitter, and LinkedIn.
Special Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation's control. The words "believes", "may", "will", "should", "would", "could", "continue", "seeks", "anticipates", "plans", "expects", "intends", "estimates", or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved.
PR Contact
Precision Public Relations
Matt Sheldon
917-280-7329
matt@precisionpr.co
Investor Contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
arec@jtcir.com
RedChip Companies Inc.
Todd McKnight
1-800-RED-CHIP (733-2447)
Info@redchip.com
Company Contact:
Mark LaVerghetta
Vice President of Corporate Finance and Communications
317-855-9926 ext. 0
investor@americanresourcescorp.com
SOURCE: American Resources Corporation
View source version on accesswire.com:
https://www.accesswire.com/661231/American-Resources-Corporation-Selected-as-a-Member-in-US-Department-of-Energy-Contract-to-Assess-Critical-and-Rare-Earth-Elements-in-Coal-Resource-Feedstocks
https://www.otcmarkets.com/stock/AREC/news/story?e&id=1980578
Here's the Release: QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
Press Release | 08/25/2021
Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared QSAM’s investigational new drug (IND) application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer.
“This IND clearance is another major milestone for QSAM and the advancement of CycloSam. We expect to commence our Phase 1 open-label dose escalation trial in bone cancer patients by the end of this year. These trials will be intended to investigate the efficacy, safety, tolerability and pharmacokinectics of CycloSam to establish the optimal dose for pivotal Phase 2/3 clinical trials,” stated the Company’s Co-Founder and CEO, Douglas R. Baum. “The clearance of our IND also continues to validate our data-driven approach in oncology drug development and sets the stage for additional aggressive efforts we are undertaking in pediatric and adult cancer therapies.”
CycloSam is expected to be a significantly improved formulation of a previously FDA-approved radiopharmaceutical. This novel drug candidate utilizes both a more efficient method of isotope manufacturing and an advanced chelation technology which may potentially allow for repeated dosing of patients with bone cancer in an effort to halt or reverse tumor growth.
About QSAM Biosciences:
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology is CycloSam® (Samarium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed a previous FDA-approved and commercially available radiopharmaceutical product indicated for pain palliation. QSAM is led by an experienced executive team and Board of Directors that have completed dozens of FDA approvals and multiple successful biotech exits.
CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial successfully performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium-154 impurity) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat primary and secondary bone cancers. Since CycloSam® has the ability to deliver targeted radiation selectively to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation, and in procedures to reduce external beam radiation to bone tumors. This multi-patented drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam®.
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Announces-FDA-Clearance-of-IND-for-Samarium-153-DOTMP-CycloSam-an-Investigational-Radiopharmaceutical-f?id=317971
NEWS 8/18/21 American Resources Corporation Finalizes Site Selection for Chromatography Rare Earth Element Isolation and Purification Facility
*The operation will be one of the first and only commercial scale facility able to purify and isolate rare earth elements in the United States
*Company's chromatography process utilizes the most environmentally-safe purification method and eliminates the need to rely on China for the final steps in the rare earth element refining process
*Facility will be designed with multiple production lines to process various feedstocks from its "Capture. Process. Purify." technology chain
FISHERS, IN / ACCESSWIRE / August 18, 2021 / American Resources Corporation (NASDAQ:AREC) ("American Resources" or the "Company"), a next generation and socially responsible supplier of raw materials to the new infrastructure and electrification marketplace, today announced that it has finalized its site selection to build its first commercial scale rare earth element purification and isolation facility in the United States. The secured site provides 6.9 acres of developable land with the goal of scaling into an 80,000 square foot facility for purifying and isolating rare earth and critical elements utilizing ligand assisted displacement ("LAD") chromatography technology. The site is based in Noblesville, IN in an existing industrial area that provides access to commercial water and power, and well located for convenient logistics.
Mark Jensen, Chairman and CEO of American Resources Corporation commented, "We have set a goal to be one of the first to produce an isolated and purified rare earth element in the United States on a commercial scale and have now secured a site that is well suited to scale our facility to commercial production. With this facility we are confident that we will be able to accomplish our goals. Our feedstocks are abundantly available and cost effective in the domestic market with approximately $3 billion worth of rare earth elements going to landfills from end-of-life products every year, and over 1 billion tons of fly ash landfilled, which is made attractive given our processes' ability to utilize favorable biproduct economics. This is an exciting moment for our team as we can now finalize the designs and begin ordering components for the build phase of this project."
The Company's REE purification facility will leverage LAD chromatography through its previously announced, exclusively license in concert with Hasler Ventures and partnership with Purdue University. Its technology is being designed to handle a multitude of feedstocks, including recycled permanent magnets, lithium-ion batteries, as well as various coal-based waste and byproducts such as fly ash, and is a significantly environmentally safer purification process compared to conventional solvent-based extraction methods.
The facility represents the final stage of American Resources Corporation's REE process chain, defined as "Capture. Process. Purify.", enabling the Company to commercially produce rare earth oxides, lithium, and cobalt from domestic sources. The facility will allow American Resources Corporation to be a first mover to purify and isolate the elements for sale directly to manufacturers of green technology components such as permanent magnets and batteries in the United States.
https://www.otcmarkets.com/stock/AREC/news/story?e&id=1975303
Pretty great day for the stock so far...
So far our Volume Weighted Average Price (VWAP) is just under 41 cents.
I think it's clear that we're heading for higher ground.
Basically, this is asking??? Any sellers here?? Come on Sellers!!
Almost has to be worth a buck or two... wouldn't you think?
Check this out!!!
BIG NEWS!! QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma
08/18/2021
Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has approved QSAM’s application for Orphan Drug Designation of CycloSam® in the treatment of patients diagnosed with osteosarcoma.
Osteosarcoma is the most common form of bone cancer in children and young adults (ages 15-39) with primary high-grade bone malignancy. Out of five patients who develop or present with metastatic osteosarcoma bone cancer, only one will survive. There have been few advancements over the last 40 years for this deadly disease, and accordingly, there is a large unmet market need for a better treatment that is more efficacious against pediatric osteosarcoma and better tolerated by patients.
“Receipt of Orphan Drug Designation is an important accomplishment for our bone cancer program and for our company. This designation further validates our data-driven approach in oncology drug development and sets the stage for additional aggressive efforts we are undertaking in pediatric and adult cancer therapies,” stated the Company’s CEO, Douglas R. Baum. “Orphan Drug Designation is designed to provide a number of benefits, most notably, seven years of market exclusivity, which complements our growing portfolio of issued patents that we expect will provide us enhanced commercial and market protections.”
Baum continued: “This orphan designation is one of several milestones we have achieved since we started last year working to bring CycloSam through the clinical trial process and ultimately, with FDA approval, to market. We are excited to advance this groundbreaking research to help patients suffering from this devastating disease where the benefits of current treatment options are very limited.”
CycloSam is believed to be a significantly improved formulation of a previously FDA approved radiopharmaceutical. This novel drug candidate utilizes both a more efficient method of isotope manufacturing and an advanced chelation technology which may potentially allow for repeated dosing of patients with bone cancer in an effort to halt or reverse tumor growth.
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Receives-Orphan-Drug-Designation-from-FDA-for-CycloSam-in-the-Treatment-of-Osteosarcoma?id=317010
I’m very pleased to hear your good report that your soon responded well.
Thanking God with you!!
Psst. Did you see today’s news?
Another building block. Everything that QSAM has done and released has been in the direction of building the company’s future.
I think it could be an incredible ride!
NEWS QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Receives-Patents-in-Japan-and-Canada-Strengthens-Licensed-IP-Portfolio-in-Key-Markets?id=315852
Press Release | 08/11/2021
Palm Beach, FL, Aug. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the countries of Japan and Canada have granted patents covering “high purity therapeutic bone agents” in connection with the Company’s CycloSam technology. The United States Patent & Trademark Office (USPTO) issued a patent on this innovation last year.
The patents in Japan and Canada cover technology licensed exclusively on a worldwide basis by QSAM from IGL Pharma, Inc. that protects the use of “low specific activity” Samarium-153. This critical component in CycloSam significantly lowers the amount of long-lived impurities, namely Europium, which may allow for multiple dosing regimens in different types of cancer treatment. The “low specific activity” attribute also allows for the radioisotope to be harvested from the nuclear reactor on a daily basis, instead of weekly, which may permit increased production and facilitate a more efficient and timely supply chain to patients if ultimately approved for commercial use by the FDA.
“We are pleased that the patent offices of Japan and Canada have recognized the novelty of our scientific discoveries and innovations on this key element to CycloSam. This expands our IP estate, consisting of 15 patents among 3 distinct patent families, and broadens our potential commercial market for what we believe can be an important therapy for both primary and secondary forms of bone cancer,” stated Douglas R. Baum, CEO of the Company.
About QSAM Biosciences:
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology is CycloSam® (Samarium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical? developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. QSAM is led by an experienced executive team and Board of Directors with dozens of FDA approvals and multiple successful biotech exits.
CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial successfully performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat primary and secondary bone cancers. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation, and in procedures to reduce external beam radiation. This multi-patented drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models and veterinary treatment of cancer in dogs. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam®.
Trading was halted for the last few minutes.
If you go back to the financials of 2019 and 2020, I forget which, but the company was paying for incurred expenses with shares. Generally, venders that took shares for services of products, are mostly looking to exchange shares for cash regardless of the current price.
I don't think this can account for everything, but when I first came into AREC's universe (2018) there were something like 110,000 shares in the public float. Since that time a number of financings were done, I believe almost all were at higher levels than we're currently trading.
We shall see.
Makes sense to me. I don't know that this is what is driving the current price, but I would not be surprised.
Venture capitalists promise companies the world, but when it comes to delivering, they get themselves and their clients the best possible prices.
Each quarter and dollar make a big difference when multiplied by hundreds of thousands and millions in financing.
I'm not sure how SPACs work or their dividends structure works. Sorry.
The push downward has been pretty relentless. On some of the run days... the float traded multiple times... and even the outstanding shares traded hands at three and four times our current levels.
The current (downward) trend seems to be feeding itself with new sellers all the way down.
Not sure if you've looked at a comparable company Ramaco Resources (Ticker: METC ). They're a producing met coal company and with more outstanding shares and are trading between $7 and $8 per share... actually just checked $8.08.
I'm pretty sure AREC is more streamlined and thus should be able to produce met coal at lower prices and thus higher margins.
As you're apt to say..
so we watch.
From my perspective this next step is pretty big news. Walmart, eBay, and Amazon are nice, but Applied Magix was just a little fish in a pretty big ponds. Today’s news shows that SPYR is serious about becoming a technology company that is actually utilizing some of the technology that’s available out there to drive and increase their sales.
It seems Applied Magix plans to continue releasing new products and a growing revenue stream. I think marketing our current and future products like this is a great move!
Also in SPYR’s disclosure statement there’s a not so cryptic hint of the direction the company is hoping to go.
“SPYR continues to identify and target acquisitions that will grow its footprint in the industry and expand the products it offers consumers, including companies developing artificial intelligence (AI) and smart-technology products. “
It might just be wishful thinking on their part, but it sounds to me that Applied Magix isn’t the only or last acquisition that SPYR hopes to bring into its corporate structure.
Assuming they are successful at this, the share price won’t be staying at these paltry levels much longer.
NEWS 8/3/2021 SPYR Technologies Expands Marketing Initiatives to Aggressively Accelerate Sales Growth for its MagixDrive Wireless CarPlay Devices
https://www.otcmarkets.com/stock/SPYR/news/SPYR-Technologies-Expands-Marketing-Initiatives-to-Aggressively-Accelerate-Sales-Growth-for-its-MagixDrive-Wireless-CarP?id=314511
08/03/2021 GREENWOOD VILLAGE, CO / ACCESSWIRE / August 3, 2021 / SPYR, Inc. dba SPYR Technologies (OTCQB:SPYR), a technology company that through its subsidiary, Applied Magix, Inc., develops and resells Apple® ecosystem compatible products with an emphasis on the growing multi-billion-dollar smart home market, today announced the engagement of TVA Media Group (TVA) to assist with its marketing initiatives to accelerate the sales growth for its MagixDrive wireless Apple CarPlay devices.
As part of the engagement, TVA will produce two national broadcast TV commercials designed to sell MagixDrive by means of direct response by the consumer. These commercials will air nationwide at a minimum of 48 times in every major city within the U.S., on national cable and/or satellite channels which is the equivalent of 10,000 localized ad spots. Additionally, MagixDrive will be featured as a Top Story during the campaign on the homepage of TVA's sponsored news portals, which include http://www.entertainmentworldnews.tv, www.healthworldnews.tv and www.businessworldnews.tv. Based upon the current production schedule, the commercials are expected to air in October 2021.
"Engaging TVA Media is exciting and the most effective strategy to help us garner the visibility and traction we need to jumpstart sales on our MagixDrive devices," commented Dr. Harald Zink, CEO of Applied Magix. "We will also utilize these commercials on our websites and social media accounts in synergy with TVA's marketing initiatives," noted Dr. Zink.
About TVA Media Group
TVA has a 34-year history of creating successful productions and media campaigns for Fortune 500s, startups, non-profits, and government agencies worldwide. Clients include 6 Flags, Ajinomoto, Best Buy, Canon, Cessna, Epson, Jacuzzi, Jenny Craig, Lexus, Marriott, MasterCard, Sitelock, Sony, StreetStrider, Teradata, Ubisoft, Universal Studios, Verizon, and Viking Cruises.
TVA has an A+ rating with the BBB, Class 1 D&B credit rating, hundreds of client references and case studies covering 40 categories; and has won every major award in advertising, DRTV and PR. See https://www.tvamediagroup.com.
About SPYR Technologies
SPYR Technologies (SPYR) is a technology company which, through its wholly-owned subsidiary, Applied Magix Inc., operates in the "Internet of Things" (IoT) market, develops and resells Apple® ecosystem compatible products with an emphasis on the growing multi-billion-dollar smart home market. SPYR continues to identify and target acquisitions that will grow its footprint in the industry and expand the products it offers consumers, including companies developing artificial intelligence (AI) and smart-technology products.
Investors can learn more about SPYR and AppliedMagix at: https://ir.spyr.com/.
LL. I just posted a reply.
Well the mystery of when AREC will announce their earnings is solved.
AREC has scheduled its earnings release for August 11, 2021 at the Market close 4:00 PM EDT.
We’ll, I guess the proof will be in the pudding. Since just before the name change from Strongbow to Fortem Resources I’ve been a shareholder. For a while my position was worth half Million.
As the stock traded up to $3.99 I had done some staggered sell orders at 25 cent increments. Like everyone who held through the initial rise and subsequent decline, I wish I had sold more at higher prices.
There was a point where I consolidated my holdings into what I thought was a pretty sure thing. At that point I owned relatively few shares of FTMR compared to what I had and now do.
Thankfully, my consolidation plan worked well and I was able to re-diversify my holdings.
All to say I think FTMR shareholders will eventually be abundantly rewarded.
Could I be wrong? Sure. We’ll find out eventually.
NASDAQ bid $8.80. Ask $15.15
We’ll see.
I also enjoyed reading this.
Just released... KAVL has been uplisted to NASDAQ
https://www.otcmarkets.com/stock/KAVLD/news/story?e&id=1954374
Kaival Brands to Commence Trading on Nasdaq
Listing is effective Thursday, July 29, 2021
GRANT, Fla., July 27, 2021 /PRNewswire/ -- Kaival Brands Innovations Group, Inc. ("Kaival Brands," the "Company," or "we"), the exclusive global distributor of products manufactured by Bidi Vapor, LLC ("Bidi Vapor"), announced today that the Nasdaq Stock Market LLC has approved the listing of the company's common stock on the Nasdaq Capital Market ("Nasdaq"). The ticker symbol will remain unchanged, as "KAVL" and the stock will begin trading on Nasdaq at the opening of the market on Thursday, July 29, 2021, but will continue trading on the OTCQB until the market close on Wednesday, July 28, 2021.
"Kaival Brands to Commence Trading on Nasdaq on Thursday, July 29, 2021"
Niraj Patel, the Company's Founder and Chief Executive Officer, stated, "I am pleased to announce that the Company has been approved to begin trading on Nasdaq. This event represents another monumental milestone in our Company's short history."
"We have worked diligently to achieve this goal and are humbled and grateful on the inclusion to the Nasdaq," said Mr. Patel. "We are more enthusiastic than ever about being able to harness Kaival's exciting potential."
"Step by step, we continue our work to build a world class, global organization – our elevation to Nasdaq represents a very large strategic evolution for the Company," noted Eric Mosser, Chief Operating Officer of Kaival Brands.
Bidi Vapor's founding mission is to provide recreational, non-combusted alternatives for adult cigarette smokers. Both Kaival Brands and Bidi Vapor are vehemently opposed to all illegal underage tobacco use, including ENDS use, by minors. We are committed to preventing youth use of ENDS, responsibly marketing to adult tobacco users 21 and over, working with law abiding retailers and distributors, and complying with all federal and state laws and taxes applicable to the distribution of the BIDI®? Stick and the BIDI®? Pouch including, but not limited to, the Family Smoking Prevention and Tobacco Control Act ("TCA"), the Food, Drug and Cosmetic Act ("FDCA"), and the Prevent All Cigarette Trafficking ("PACT") Act. We are further committed to developing science to support the continued marketing of our products as appropriate for the protection of the public health and engaging with state and federal authorities to promote enforcement and the removal of counterfeit, non-compliant and youth-targeting ENDS products from the market.
Mr. Patel, the Company's President and Chief Executive Officer, owns and controls Bidi Vapor. As a result, Bidi Vapor and the Company are considered under common control and Bidi Vapor is considered a related party.
Inflection Partners, LLC and Morgan, Lewis & Bockius LLP are acting as capital markets advisors and legal counsel, respectively, to Kaival Brands in connection with the uplist to Nasdaq.
ABOUT BIDI VAPOR
Yeah I think the time for building a position at the bid has passed. We’ll see.
Agreed. Before and After the reverse I had been accumulating. At one point I owned 10% of the public float. With the restructuring a lot of debt was converted into shares and some added to the float.
I sold most of my position as it traded up afterwards. In the last month I’ve built up a modest position.
Thanks for posting. I hadn’t seen this until just now.
SPYR continues taking methodical step after step. While we’d all like it if the company would suddenly become mature, fully functional, and profitable. But realistically there are dozens of steps to becoming and growing into that.
For now each step in the right direction is a link in the chain that will hopefully lead to success. I think the current stock price reflects that the company isn’t yet what it hopes to become.
That being said, if one believes that SPYR HAS A FUTURE and a shot at becoming a success, the current price offers a pretty hefty rate of return.
I might be dreaming, but if they become anything… or at least for a time look like they might, I think 50 cents to $1.00 is within easy reach. That would be an increase 10 to 20 times the current price.
Hey, SPYR is now listed as OTCQB. It says that SPYR was an OTCQB Member Since 07/2021
I don't know that this is a huge deal... but it certainly seems like a step in the right direction.
Here's a summary of the qualifications:
Eligibility Requirements
* U.S. companies must have audited annual financials by a PCAOB auditor. (Tier 2 Regulation A Companies are exempt from requirement to use a PCAOB auditor for their initial audit)
*Meet minimum bid price test of $0.01
*Not be in bankruptcy
* Have at least 50 Beneficial Shareholders, each owning at least 100 shares
* Have a freely traded Public Float of at least 10% of the total issued and outstanding of that security.
* Companies with a freely traded Public Float of at least 5% (and $2 million in market value of public float), or a separate class of securities traded on a national exchange may apply for an exemption (see OTCQB Standards)
* Have a transfer agent that participates in the Transfer Agent Verified Share Program (US Companies only)
* International companies must be listed on a Qualified Foreign Exchange (or SEC Reporting) and submit a Letter of Introduction from an approved OTCQB Sponsor
Reporting Requirements
* Meet one of the following Reporting Standards:
* SEC Reporting Standard
* Regulation A Reporting Standard (Tier 2)
* U.S. Bank Reporting Standard
* International Reporting Standard
* Alternative Reporting Standard
*Timely disclosure of material news
Corporate Governance Requirements (Alternative Reporting only)
* Have a board of directors that includes at least two Independent Directors
* Have an Audit Committee, a majority of the members of which are Independent Directors
* Verification Requirements
* Maintain a Verified Company Profile
* Post initial and annual verification and management certification
Here's a full list: https://www.otcmarkets.com/files/OTCQB_Standards.pdf
Hey Little John,
Last year they reported 2nd Quarter on 7/23/2020.
My understanding is that they have until mid-August to file (45 days from end of quarter).
I think you’re right. QSAM is found a lot right. I don’t have any way to know how much paper remains, but it certainly seems to be tailing off.
Thanks BB: I’ve been out is pocket and hadn’t seen this release. Like so many other factors with the company, this release is pretty solid and is yet another building block that points to a remarkably bright future.
We shall see!
Looks like Good information to me. Thanks.
It’d be nice to hear some updates about production rates or estimates!!
Informative article and good read. The highest quality steel pretty much requires high quality metallurgical coal.
Well, I’m interested in KAVL and somewhat committed to its future.
I recently signed on as a Moderator. I don’t know that I have a lot to offer, but I think Kaival Brands will have an interesting future. And hopefully, I’ll be a part of it.
Thanks. Other than the previous and current stock price, there’s a lot to love about KAVL.
Will we reach the sky high forecasted sales for fiscal 2021? Not sure. But realistically, find me another stock with even half as much revenue or even a fourth of the projected revenue, and I’ll be impressed.
KAVL is quickly becoming a world class and world-wide company… I suspect we’ll be hearing about product shipments to numerous foreign customers before long.
I don’t think it will take much for people’s perception of KAVL and potential begins to be reflected in the stock price.